Compare Citius Pharmaceuticals Inc (CTXR) vs Hasbro, Inc. (HAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Hasbro, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Hasbro, Inc. trades at $94.06 (market cap $13.05B). The key difference: Hasbro, Inc. is far larger — about 958.1× Citius Pharmaceuticals Inc's market cap, and Hasbro, Inc. pays a 3.03% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Hasbro, Inc. for 97 Days on average.
| CTXR | HAS | |
|---|---|---|
Market Cap | $13.62M | $13.05B |
Volume | 132,438 | 1,207,655 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $105.88 |
52-Week Low | $0.48 | $70.95 |
Typical Hold Time | 17 Days | 97 Days |
Enterprise Value | $3.79M | $15.24B |
Dividend Yield | — | 3.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Hasbro (HAS) trades at $94.22, up 3.82% today, showing strong momentum after recent earnings beats. The stock maintains a bullish technical stance with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, the company demonstrates robust profitability with 64.41% gross margins and impressive ROE of 167.83%, despite a net loss in 2025. Analyst consensus remains positive with 51.52% buy ratings and a $107.60 price target, representing 14% upside potential from current levels.
Investment outlook appears favorable with strong gaming segment growth and cost-saving initiatives driving projected 2026 net income of $794 million. Key risks include high debt levels at 59.09% debt-to-asset ratio and competitive pressures in the toy industry. The upcoming Q3 2026 earnings report on October 20 will be crucial for validating the company's turnaround trajectory and growth projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →
